Drug Safety Cmte. To Review Accutane iPLEDGE Program
This article was originally published in The Pink Sheet Daily
FDA’s Drug Safety & Risk Management Advisory Committee may discuss measures to evaluate the revised risk management program during its Feb. 10 meeting.
You may also be interested in...
Wholesalers, pharmacists, prescribers and patients will have added responsibility under the iPLEDGE program.
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.